CAR-T Cell Therapy Targeting to CD19 for R/R ALL

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    The First Affiliated Hospital of Soochow University
Updated on 3 February 2022


Refractory and relapsed (R/R) acute lymphoblastic leukemia (ALL) patients with active disease always have a dismal outcome. Chimeric antigen receptor (CAR) T-cell therapy targeting to Cluster of Differentiation Antigen 19 (CD19) has been proved as a potent approach to attain remission in B-cell R/R patients. Therefore, the investigators conduct a trial to evaluate the the efficacy and safety of locally producing CAR T cells targeting CD19, and to analyze the outcome of enrolled B-cell ALL patients with active disease or persistent residual disease.

Condition Acute Lymphoblastic Leukemia With Failed Remission
Treatment CAR T-cell therapy
Clinical Study IdentifierNCT03919240
SponsorThe First Affiliated Hospital of Soochow University
Last Modified on3 February 2022


Yes No Not Sure

Inclusion Criteria

Diagnosed as CD19+ B-cell acute lymphoblastic leukemia
Fail to achieve remission, or with persistent residual disease after at least 2 cycles of consolidation
With an estimated survival of higher than 3 months (according to investigator's judgement)
Sufficient organ function: left ventricular ejection fractions 0.5 by echocardiography, creatinine < 1.6 mg/dL, aspartate aminotransferase/aspartate aminotransferase < 3 x upper limit of normal, bilirubin <2.0 mg/dL
Karnofsky performance status 60 or ECOG 2

Exclusion Criteria

Intolerant to immunosuppressive chemotherapies
With active infection or other uncontrolled complications
With history of seizure
Active hepatitis B or hepatitis C infection and HIV infection
Pregnant or lactating women, or patients refusing to take effective contraception measures
Other contraindications that considered inappropriate to participate in this trial (according to investigator's judgement)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note